Advertisement
AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Oct 3, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aiello, A. E.
Right arrow Articles by Foxman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aiello, A. E.
Right arrow Articles by Foxman, B.
Related Collections
Right arrow Community Health
Right arrow Ethics
Right arrow Other Health Financing
Right arrow Health Policy
Right arrow Other Health Service Delivery
Right arrow Other Infections
Ethical Conflicts in Public Health Research and Practice: Antimicrobial Resistance and the Ethics of Drug Development

Allison E. Aiello, PhD, MS, Nicholas B. King, PhD and B. Foxman, PhD

Allison E. Aiello is with the Center for Social Epidemiology and Population Health, University of Michigan School of Public Health, Ann Arbor. Nicholas B. King is with the Department of Bioethics, Case Western Reserve University, Cleveland, Ohio. B. Foxman is with the School of Public Health and the Center for Molecular and Clinical Epidemiology of Infectious Diseases, University of Michigan, Ann Arbor.


Figure 1
View larger version (11K):

[in a new window]
  		FIGURE 1—— Number of new drug classes introduced between 1935 and 2005

a Sulfanomides.

b Penicillins, aminoglycosides, cephalosporins.

c Chloramphenicol, tetracyclines, macrolides, lincosamides, streptograms.

d Glycopeptides, rifamycins.

e Nitroimidiazoles, quinolones.

f Trimethoprim.

gOxazolidinones

hLipopeptides.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Public Health Association